Evommune (EVMN) Equity Ratio (2024 - 2026)

Evommune (EVMN) reported Equity Ratio of 0.94 for Q1 2026, up 3.35% quarter-over-quarter from 0.91 in Q4 2025.

Evommune (EVMN) Equity Ratio (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of Equity Ratio data on file, last reported at 0.94 in Q1 2026.

Equity Ratio for Q1 2026 came in at 0.94, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 0.94 (changed N/A YoY), and the FY2025 annual result was 0.91, up 148.19% from the prior year.
Equity Ratio advanced to 0.94 in Q1 2026 per EVMN's latest filing, from 0.91 in the prior quarter.
Over five years, Equity Ratio peaked at 0.94 in Q1 2026 and troughed at 2.17 in Q3 2025.
A 3-year average of 0.55 and a median of 0.49 in 2025 frame the typical range for Equity Ratio.
On a YoY basis, Equity Ratio climbed as much as 148.19% in 2025 and fell as far as 148.19% in 2025.
A 3-year view of Equity Ratio shows it stood at 1.9 in 2024, then surged by 148.19% to 0.91 in 2025, then advanced by 3.35% to 0.94 in 2026.
Business Quant data shows EVMN's Equity Ratio at 0.94 in Q1 2026, 0.91 in Q4 2025, and 2.17 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Ratio (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	191.07
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	0.98
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	0.04
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.58
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	0.42
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	0.73
9	Abivax	91.96 Bn	91.96 Bn	-	0.79
10	Evommune	695.29 Mn	483.82 Mn	-	0.94

Download Data